Primary medical therapy is used to reduce tumour size prior to surgery in women with locally advanced breast cancer. Optical tomography is a functional imaging technique using nearinfrared light to produce three-dimensional breast images of tissue oxygen saturation and haemoglobin concentration. Its advantages include the ability to display quantitative physiological information, and to allow repeated scans without the hazards associated with exposure to ionising radiation. There is a need for a non-invasive functional imaging tool to evaluate response to treatment, so that non-responders can be given the opportunity to change their treatment regimen. Here, we evaluate the use of optical tomography for this purpose. Four women with newly diagnosed breast cancer who were about to undergo primary medical therapy gave informed and voluntary consent to take part in the study. Changes in physiological and optical properties within the tumour were evaluated during the course of neoadjuvant chemotherapy. Optical imaging was performed prior to treatment, after the first cycle of chemotherapy, halfway through, and on completion of chemotherapy. Images of light absorption and scatter at two wavelengths were produced, from which images of total haemoglobin concentration and oxygen saturation were derived. All patients that showed a good or complete response to treatment on MRI showed a corresponding recovery in the haemoglobin concentration images. Changes in mean tumour total haemoglobin concentration could be seen four weeks into treatment. The tumour oxygen saturation was low compared to background in three out of four patients, and also showed a return to baseline over treatment. Optical imaging of the breast is feasible during primary medical therapy and can be used to assess response to treatment over six months.
Introduction

Optical Mammography
The use of near infrared (NIR) light to examine the breast has been actively researched since the 1980s, when developments in source, detector, and computing technology made diffuse optical imaging feasible (1). Optical techniques provide discrimination between tissues based on their optical properties, obtained from measurements of NIR transmitted light. The relatively low absorption by water at NIR wavelengths allows light to travel centimeters through tissue. The different absorption spectra of chromophores, such as deoxyhaemoglobin (Hb), and oxyhaemoglobin (HbO 2 ) allows the calculation of various physiological parameters such as the concentration of haemoglobin [HbT] (2-4) and blood oxygen saturation (SatO 2 ) (5-7). The field of timeresolved optical measurements of the breast has been investigated since the early 1990s (8-10). The early pioneering work on the models of light transport in tissue, and image reconstruction algorithms are reviewed by Arridge and Hebden (11) and Dehghani et al. (12) .
There have been a number of reviews published in the past few years that cover the optical properties of healthy breast tissue and the changes that occur to these properties with physiological and pathological changes in the breast (13-16). Leff et al. carried out a systematic review of clinically orientated studies involving approximately 2,000 women in whom optical mammography had been used to evaluate the healthy or diseased breast (13). The mean absorption, scatter, [HbT] and SatO 2 for healthy tissue in both pre-and postmenopausal women, malignant tumours and benign lesions from these 2,000 women were calculated. Results suggested that tumours contain approximately three times the haemoglobin concentration of background healthy breast tissue ((65 6 34 vs. 21 6 6) mM). A weighted average sensitivity and specificity for lesion vs. normal breast tissue was calculated from 227 lesions from five studies (17) . The weighted average sensitivity and specificity were 87.9% and 89.3% respectively.
Primary Medical Therapy
Primary medical therapy is the terminology that encompasses neoadjuvant chemotherapy and endocrine therapy administered pre-surgically. Primary medical therapy was introduced in the 1970's for inoperable breast tumours in an attempt to make them operable by mastectomy or downsizing to allow breast conserving surgery (18). In the 1980s neoadjuvant chemotherapy was recommended for tumours larger than five cm and for one or two cm tumours in the 1990s (19) . While neoadjuvant chemotherapy does not increase overall survival, it does increase the chance of successful breast conserving surgery (18, (20) (21) (22) .
Knowledge of treatment response is important in determining prognosis and tailoring pharmacological and surgical needs for individual patients. Correct estimates of residual disease after chemotherapy allow selection of patients for breast conservation surgery and help to reduce the rates of repeat surgery (23). It may require several months from the beginning of chemotherapy until surgery permits a final histopathological assessment of the cancer. Therefore it is important to detect and predict poor-responsiveness as early as possible in order to avoid delays in surgery and increase effectiveness of therapy.
Current Monitoring of Primary Medical Therapy
Several imaging modalities have been used to assess early response to chemotherapy. Mammograms and breast ultrasound are two common imaging methods for predicting residual tumour size in the primary site after neoadjuvant chemotherapy (24) (25) (26) . Magnetic resonance imaging (MRI) has emerged as the optimal imaging method for characterizing residual disease and monitoring response for neoadjuvant chemotherapy. Breast MRI (generally using a contrast agent) outperforms ultrasound, mammography and physical examination, alone or in combination, at detecting residual disease and in determining initial extent of disease during presentation (27). However, MRI's spatial resolution is worse than mammography, so it cannot accurately predict tumour size or identify small lesions (28) . None of the current imaging modalities are able to reliably identify active foci of microscopic disease scattered in the breast (29).
Optical Imaging of Treatment Response
Diffuse optical imaging (DOI) and diffuse optical spectroscopy (DOS) of breast disease have been researched extensively over the last twenty years with clinical studies appearing in the literature (30) (31) (32) (33) (34) . It has been shown that tumours exhibit a distinctive optical signature compared to healthy breast tissue (13). The [HbT] of malignant tumours is about three times that for healthy breast tissue ((65 6 34) mM vs. (21 6 6) mM) but there is no reported difference in SatO 2 ((66 6 24)% vs. (67 6 6)%) (13). DOI and DOS have a number of advantages and disadvantages (17) which will influence the clinical roles they can fulfil. Since optical scanning is safe, repeated scans over a long period can be performed without the exposure risks associated with x-ray imaging. The sensitivity to changes in tissue composition and physiology is also an advantage. The major disadvantage is the relatively poor spatial resolution, typically 8-11 mm (17), making it unsuitable for a screening method.
The use of DOS and DOI to assess response to primary medical therapy is very much in infancy, with papers appearing in the literature from 2004 onwards (35). DOS and DOI could prove useful as an affordable, non-invasive imaging modality to monitor response to primary medical therapy. Assessing the response could be an ideal application for optical methods, as there is less need for spatial information, but the ability to perform multiple scans over a period of time and acquire physiological information plays to the strengths of the techniques. The information obtained could be used to inform treatment plans. Furthermore, images reconstructed showing hypoxia could influence treatment decisions for radiotherapy.
The Beckman Laser Institute at University of California Irvine (UCI) has studied the suitability of DOS to monitor neoadjuvant chemotherapy using DOS (35) (36) (37) (38) (39) (40) . A hand-held optical probe is placed against the breast and frequency domain measurements of reflected NIR light are made at points on the surface of the breast. Different chromophore concentrations and physiological properties at different wavelengths are obtained. Changes in optical and physiological parameters could be seen within days of starting primary medical therapy (36). Soliman et al. found that the optical and physiological parameters measured with DOS in patients that responded to treatment were significantly different to those that did not respond (41). The responding patients had much greater decreases in [Hb] , [HbO] , water content and scattering power (an indicator of cell density) at Week 4 of treatment compared to the non-responding group.
The research group at the University of Connecticut have also used a hand held NIR probe to record data from multiple locations over the affected breast and the contralateral breast (42). The frequency-domain optical measurements made using the probe provide both spectroscopic information and topographic maps of total haemoglobin concentration. The NIR probe has been integrated into an ultrasound probe, which is used to localise the tumour. Eleven women were studied during treatment with US/NIR data collected at two, four and six weeks during chemotherapy and prior to surgery. A parameter known as tumour vascular blood volume index (BVI) was calculated from the sum of the total haemoglobin concentration and tumour volume. Patients were categorised into four groups: total or near-total therapeutic effect (A), more than 50% therapeutic effect (B), less than 50% but visible therapeutic effect (C), and no therapeutic effect (D). The % reduction in BVI on treatment completion was (71 6 7)% for group A, (54 6 4)% for group B and (13 6 30)% for group C.
Tomographic images of the breast while monitoring neoadjuvant chemotherapy has been carried out at the University of Pennsylvania using a combined frequency domain and continuous wave clinical system, where the prone breast is lightly compressed in an Intralipid-filled tank. An early paper published in the area was a case study of a 35 year old woman with invasive ductal carcinoma, who was imaged at 10 weeks, 14 weeks, and 19 weeks after the start of chemotherapy (43). A high region of [HbT] , corresponding with the region of the tumour on MRI, was still seen in the images after the fifth chemotherapy cycle in the DOI image. The high [HbT] region was seen to shift towards the outside of the tumour. A high m s region in the area of the tumour shrank in size over the course of treatment. A decrease in contrast for SatO 2 between tumour and normal tissue was also seen after the 5 th chemotherapy cycle.
3D tomographic images of the breast over a course of primary medical therapy have been obtained by the Biomedical Optics group at Dartmouth College, using a frequency domain system. A patient interface of three adjustable rings, each with 16 sources and 16 detectors was used. The rings are adjusted so they couple with the surface of the breast, allowing the generation of 3D images of the uncompressed breast. Early physiological changes in the tumour have been used to retrospectively predict outcome (44) . A change in [HbT] over the course of treatment was the only parameter with a significant difference between patients who responded to treatment and those that did not respond. The changes in size of the tumour ROI was not significant after the first cycle, but was substantial over the course of treatment, indicating that changes in the size of the tumour is not a good early indicator of response, when compared to changes in [HbT] . In a study of eleven women by Pakalniskis et al., there was a decrease in mean [HbT] levels over treatment in the tumour ROI in women who showed a pathological complete response (pCR) on finishing treatment, but not in women with a partial response (45). This change in [HbT] correlated with mean blood vessels density, confirming the angiogenic origin of the observed changes in [HbT] .
Contributions of Paper
In this paper we summarize the results of repeat optical scans performed on a subset of patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. These are the first long-term studies monitoring treatment using timeresolved, photon-counting technology. As discussed, previously published work use frequency domain systems. These are faster than photon-counting time-domain systems (13) but photon counting systems have significantly greater sensitivity as they can detect the low light intensities that occur when imaging large volumes of tissue. Furthermore, timedomain systems provide more information about the diffuse photons and heterogeneities within the tissue and allow for more selective elimination of noisy measurements (46).
We also obtain 3D tomographic images of the whole breast without compression, which we believe is important. Studies have examined the healthy breast under different levels of compression and have found that [HbT] and SatO 2 in the tissue decrease under greater levels of compression as the blood is forced out (47). It has been hypothesised that by compressing the breast, the contrast between the healthy tissue and the tumour will be changed (48). This is because of the increased interstitial pressure within the tumour, which causes more blood to be retained in the tumour vessels than in the surrounding healthy tissue. The lack of compression is also important for patient comfort.
Our results are four patient case studies. Quantitative values of [HbT] and SatO 2 derived from images are presented. One patient exhibited a complete response to treatment using both MRI and DOI. Another patient showed a complete response in DOI images and no remaining enhancement on MRI. Tumour [HbT] reduced to background values in both patients. Another patient exhibited a fall in tumour [HbT] compared to pre-treatment images and a 22 mm lesion with Type 2 enhancement on MRI at the end of treatment. All patients show a response in SatO 2 in the tumour, with an increase or decrease towards that of background breast tissue.
The images and data also show consistent, quantitative values of [HbT] and SatO 2 in healthy breast tissue over a long period of time -up to 26 weeks in one case. The longest study we have found in literature lasted 19 weeks and then only values of tumour/background contrast were given, and no quantative values for background tissue (43). The longest study that has presented quantitative values for the background healthy tissue took place over for 10 weeks (35) . We show that the [HbT] and SatO 2 of healthy breast tissue are reproducible.
Methods
Imaging System
The UCL 32-channel time resolved optical imaging system employs a portable fibre laser (IMRA Inc., USA) which produces pulses ~2 ps in duration at 780 nm and 815 nm, interlaced with a repetition rate of 80 MHz (49, 50). The pulses are transmitted through a 32-way optical switch that illuminates each source fibre in sequence. Each source fibre is integrated along the axis of a detector fibre bundle. The bundles transmit light to four 8-anode microchannel-plate photomultiplier tubes. These produce an electronic pulse for each photon detected and are protected from overexposure by variable optical attenuators. Timing electronics (Becker & Hickl GmbH, Berlin, Germany) record the times taken for photons to travel through the illuminated medium, and produce a time-of flight histogram known as a temporal point spread function (TPSF) for each source-detector combination. Images are reconstructed using intensity and mean flight time datatypes extracted from the TPSFs (51).
Patients
Suitable patients were consented to participate in this study from among women attending appointments at Guy's and St Thomas' NHS Foundation Trust and the Lewisham Hospital NHS Trust by G.C. and D.W. Twenty two women have been recruited to the project, with 13 women having completed treatment to date. Of the patients that have completed treatment, six were being treated with neoadjuvant chemotherapy, while four were being treated for four to six months prior to surgery with neoadjuvant endocrine therapy such as letrozole. Three other patients were taking part in a clinical trial in which they received two weeks of endocrine therapy prior to surgery. Two of the patients receiving chemotherapy were lost to follow up, as one patient was operated on early during treatment due to lack of response, while one dropped out due to ill health because of treatment effects. As chemotherapy and endocrine therapy have different mechanisms of action, only results from patients who have completed neoadjuvant chemotherapy and have had three or more optical scans on completion of treatment are presented in this paper. The clinical details of these four patients are summarised in Table I .
Imaging Protocol
Patients underwent either three or four optical imaging sessions. The first scan was prior to the start of treatment. A second scan was performed after the first cycle of treatment, if possible. One patient could not attend this scan because of ill health due to treatment effects. A third and fourth scan were carried out halfway through and on completion of treatment prior to surgery. Both breasts were scanned. Images of optical absorption and scatter, [HbT] and SatO 2 were produced. Each scan took three minutes. Patients were offered a modest honorarium for taking part and transport costs were reimbursed.
The patient lies prone with her breast pendant in the patient interface, as shown in Figure 1 . This consists of a 160 mm diameter rigid hemispherical cup with thirty-one regularly spaced 10 mm diameter holes in its surface (52). Over each hole is a Perspex window and a connector for the source-detector fibre. The cup is attached to a plastic ring which fits within an aperture in a wooden Table. A coupling fluid fills the remaining space between the breast and the hemisphere (53). The fluid is made from a solution of Intralipid (a soya bean based fat emulsion) and NIR dye in de-ionised water, which provides an absorption coefficient of m a 5 0.004 mm 21 and a transport scatter coefficient of m s ′ 5 0.8 mm 21 at 800 nm (52). These are intended to be typical of the optical properties of breast tissue (13). As reported previously, imaging using the hemispherical cup employs a so-called difference approach, which involves reconstructing the changes in optical properties between the cup containing both the coupling fluid and the breast and those of the cup containing the fluid alone as a reference (53). This eliminates the effect of uncertainty and variability in the surface coupling, allowing use of intensity measurements. Detector gains, the source/detector fibre length and position, and the laser source power were kept constant for all scans. The absorption and scatter properties of the coupling fluid were measured after each scan session.
Image Reconstruction
3D images were generated from the data using the TOAST reconstruction package developed at UCL. TOAST produces 3D images of scatter and absorption coefficients (54). Image reconstruction involves iteratively adjusting the optical properties assigned to a finite element method (FEM) mesh to minimize the difference between the datatypes predicted by the model and the data (54). The model starting values are the measured absorption and scatter coefficients of the coupling fluid. The image reconstruction was performed using a conjugate gradient solver and Robin boundary conditions. We assume that the optical absorption represented in the absorption images is due to three components: HbO 2 , Hb, and a "background" component with the same absorption coefficient at both wavelengths (780 nm and 815 nm), assumed to be mainly due to lipid and water. A background value of 70% of the absorption averaged over the image was selected, based on estimates of tissue optical properties published elsewhere (55). The combination of absorption data at two wavelengths and knowledge of the appropriate extinction coefficients can be used to derive [HbT] and SatO 2 (52).
Physiological Properties and Contrast
A two-dimensional (2D) coronal slice was extracted from each 3D m a , m s ′, [HbT] and SatO 2 reconstructed image. It was selected from the 3D image at the location where the lesion contrast was maximal. A circular tumour region of interest (ROI) was then selected around the peak contrast in the 2D image. A second circular ROI was selected as background breast tissue from the rest of the image slice. This second ROI did not include the Intralipid boundary or the tumour ROI. This second ROI was changed if necessary on repeat images, to ensure only breast tissue was included in the analysis. The mean and standard deviation of the optical and physiological values for the lesion and for the rest of breast tissue were calculated, as was the contrast between the lesion and the breast. The same image slice from the contralateral breast was also analysed. The changes in contrast and in the physiological and optical properties within the tumour and the rest of the breast were evaluated during the course of neoadjuvant chemotherapy. Other groups have shown that [HbT] is the most useful and most robust parameter (56). It is the most physiologically meaningful parameter, as it correlates with blood vessel density (45). The SatO 2 of the tumour and the rest of the breast are also analysed.
Statistical Analysis
The statistical differences between measurements, e.g. tumour and healthy breast tissue at start of treatment, were calculated using a t-test with p , 0.001 taken as significant. The degrees of freedom for the t-test were calculated from the number of resolution elements in the image. The spatial resolution for the optical images was taken from previous work (57). The full-volume half-maximum (FVHM) for 3D images was calculated from phantom studies and varies from 10-40 cm 3 . We took 20 cm 3 as a suitable mid-range estimate. From this we calculated that the equivalent full width half maximum (FWHM) was 16 mm. The number of resolution elements of the image was calculated by dividing the area of the ROI by the area of one resolution element (5π.8 2 mm 2 ). This gives us the number of resolution elements for the ROI (both tumour and breast regions), which was taken to be the number of degrees of freedom for the t-test. This approach has weaknesses (e.g. the FWMH varies across the image) but gives a reasonable estimate of the number of degrees of freedom. It is unreasonable to assume that every pixel in the image is an independent measurement, as each pixel is very closely related to its neighbours. 
Results
Four women aged 31, 45, 47 and 59 undergoing neoadjuvant chemotherapy were scanned bilaterally either three or four times during their course of treatment for locally advanced breast cancer (Table I) . A total of 13 image sets was obtained. All of the chemotherapy drugs used were classical DNAdisrupting chemotherapy agents, which act by causing breaks in the DNA double helix which then cause the cell to undergo apoptosis (programmed cell death). Patient D was also given Herceptin, due to the HER2/neu positive nature of her tumour. Figure 2 shows the initial optical breast scan images for Patient A, a 45 year old women undergoing neoadjuvant chemotherapy for a Grade II carcinoma in upper outer quadrant (UOQ) of her right breast. The images of absorption and scatter are from 780 nm. An increase in absorption and [HbT] is seen in the region of the tumour, and a decrease in SatO 2 and scatter. The tumour volume was calculated on MRI to be 34 3 21 3 19 mm. On completion of chemotherapy the pathologist reported a good response to treatment with no residual enhancement. A good response to treatment means that there was at least a 30% decrease in the longest dimension of the target lesion (58). Figure 4 shows the SatO 2 in the lesion and background tissue for Patient A. The lesion shows a reduced tissue SatO 2 at the beginning of treatment of (55 6 2)% vs. (69 6 3)% in the breast (p , 0.001). The lesion SatO 2 rose over the course of treatment to (72.2 6 0.4)%, while the background SatO 2 remained constant. The contrast between the lesion and the background were also calculated. Table II shows the contrast for each parameter for each patient and scan. At Week 0, the contrast for both [HbT] and m a are both positive, with the lesion having a contrast of 1.07 times background for [HbT] and 2.62 times background for m a . SatO 2 (20.2 times background) and m s ′ (20.45 times background) are both negative. Over the repeat scans, the contrast for all four parameters decreased.
Patient A
Patient B
Patient B was a 31 year old woman with a large Grade III carcinoma in the UQ of her left breast. The pre-treatment lesion measured 58 3 41 3 51 mm on MRI with type 3 enhancement. The final biopsy results confirm a good response to treatment, and the MRI confirmed the presence of a 22 mm Grade III tumour. The patient underwent a double mastectomy following neoadjuvant chemotherapy due to the patient's age, and the triple negative nature of the lesion. Triple negative breast cancer is a subtype of breast cancer that is characterised as being more aggressive and less responsive to standard treatment and is associated with a poorer overall prognosis (59). Figure 5 shows the changes in the mean [HbT] in the lesion and the background tissue over time. The tumour [HbT] was (52 6 3) mM prior to treatment, rising to (60 6 11) mM at Week 5 and falling to (37 6 5) mM by Week 19 of treatment. There was an increase in background [HbT] at Week 4 (26 6 10) mM. This then decreased to (14 6 4) mM at the end of treatment. Data from a scan carried out half way through treatment was unusable due to technical problems. Figure 6 shows changes in the mean SatO 2 in both breast and background tissue. There was increased SatO 2 in the lesion compared to background at the start of treatment ((81 6 4)% vs. (70 6 4)%). This increased SatO 2 resolved over treatment. There was positive contrast between the lesion and the background for [HbT], SatO 2 and m a at 780 nm prior to treatment (2.1, 0.2 and 4.5 times background respectively) while the contrast for m s ′ was negligible (20.03 times background) (Table II) . Over the course of treatment there was a decrease in the contrast for m a at 780 nm, but little change in [HbT] .
Patient C
Patient C was a 47 year old woman with a Grade III lesion in the UOQ of her left breast and benign lesions in both the left and right breast (see Table I ). A final biopsy showed that the patient had a complete response to treatment. A complete response to treatment means the disappearance of all target lesions (58). Figure 7 shows the changes in the mean [HbT] in the lesion and the background tissue over the course of treatment. The tumour [HbT] was (69 6 4) mM prior to treatment, falling to (38 6 9) mM at Week 10 and then falling to (19.9 6 0.6) mM by Week 20 of treatment. Patient C also showed changes in the background tissue [HbT] over time, decreasing from (28 6 12) mM at the start of treatment, to (18 6 4) mM at the end, a decrease of 36% (p , 0.001). Data from a scan carried out after the first cycle of treatment was unusable due to technical problems. Figure 8 shows the changes in mean SatO 2 in the lesion and breast tissue over treatment. Reduced SatO 2 in the lesion is seen prior to treatment, ((62 6 2)% vs. (77 6 4)%) followed by an increase in background SatO 2 after the first cycle of treatment to (70 6 1)%. The contrast between the lesion and the background is presented in Table II . Again, greatly increased contrast for absorption is seen at the start of treatment, which decreases over treatment as does [HbT] . Figure 10 shows the mean SatO 2 . Reduced levels of SatO 2 are seen in the in the lesion compared to background at the start of treatment ((67.5 6 0.2)% vs. (70 6 1)%), which then is then followed by a decrease to (65.0 6 0.5)%. Tumour SatO 2 then increases to that of background healthy tissue towards the middle of treatment. However, the contrast between the lesion and the background is very small (Table II) . There was positive contrast between the lesion and the background for [HbT] and absorption at 780 nm prior to treatment (3 and 6 times background respectively). Over the course of treatment, there was a decrease in the contrast for [HbT] to 20.03 at the end of treatment.
Discussion
We have imaged four women, with the longest study taking place over 26 weeks. Three women were scanned four times, and one was scanned three times, resulting in 13 complete useable data sets. Both breasts were scanned, with the healthy breast data giving us an aged match control. The method is sufficiently practical to use on ill women undergoing neoadjuvant chemotherapy and none of the patients reported any discomfort during the scans. All four patients showed optical and physiological contrast compared to the rest of the breast in the region of the tumour (as confirmed on MRI) in their baseline optical scans.
Our results for background tissue in the affected breast show reproducible [HbT] values between several scans over a period of up to six months. Background values of both healthy and diseased breasts ranged from 13 to 27 mM, which is comparable to published normal values of healthy breast There is a significant difference between the tumour and the background tissue at Week 0 (p , 0.001). There is an increase in both the background tissue [HbT] and the tumour [HbT] at Week 5 (by 29% and 16% respectively), followed by a decrease in all tissues by the end of treatment. There was still a significant difference between the tumour and the background tissue at the end of treatment (p , 0.05). *denotes p , 0.001. The observed maximum total haemoglobin concentration for tumours at the start of treatment ranged from 43 mM to 69 mM, which is again comparable to published data (average [HbT] 5 65 6 34 mM) (13). Large error bars are seen for [HbT] in the tumour ROI, suggesting heterogeneity of haemoglobin distribution within the tumour, a well characterised phenomenon (63). The contrast of tumour [HbT] compared to the background [HbT] ranged from 1 to 3 times. This is comparable with published data (13).
The [HbT] in the region of the tumour returned to baseline at the end of treatment in Patient A, who had a good response based on her final clinical MRI. Patient A was classified as a good responder and the radiologists suggested that any residual tumour on MRI was either due to scarring or distortion rather than active malignant tumour tissue. There was no residual enhancement.
Patient B was classified as having a good response to treatment (in both biopsy and imaging) with a decrease in the size of the original lesion. A return to baseline of the tumour [HbT] was not seen in the optical images, though a decrease in [HbT] did occur. At the end of treatment the tumour measured 10 3 11 3 24 mm with Type 2 enhancement on MRI, compared to 50 3 33 mm with Type 3 enhancement at the start of treatment. Type 3 enhancement means that the signal from a contrast agent peaks two minutes after administration and thereafter decreases with time (64). Lesions with Type 3 enhancement are usually malignant. Type 2 enhancement means that the contrast agent signal peaks at two minutes and then remains constant. It is also suggestive of malignancy, but with less sensitivity and specificity than Type 3 (64). The presence of active tumour tissue on the final MRI corresponds with the higher [HbT] in the tumour region compared to background at the end of treatment.
Patient C had a complete response to treatment when classified by MRI and biopsy. A corresponding return to baseline for tumour [HbT] was seen in the optical images and physiological data. Tumour [HbT] fell from (69 6 4) mM at the start of treatment to (19.9 6 0.6) mM (p , 0.001).
The changes in tumour haemoglobin for Patient D suggest a complete response, while MRI and ultrasound indicate that some tumour tissue was still present at the end of treatment. The patient had a micropapillary carcinoma and the avascular nature of this type of breast cancer may explain the optical results seen (60). Also, the lesion measured 8 mm on the final ultrasound scan, which is around the lower limit of the spatial resolution for optical tomography (13) . It should also be restated that the last optical scan was taken at the treatment mid-point, not at the end of treatment and therefore does not reflect final outcome. The tumour could have regrown after the first phase of treatment.
In malignancies the values of partial pressure of oxygen in tissue (pO 2 ) are , 20 mmHg, compared to a median of 67 mmHg in normal tissue (65). Stage T3-T4 tumours have been shown to have a higher pO 2 than T1 and T2 lesions (35 mmHg vs. 24 mmHg) (65). Low blood oxygen saturation has also been observed in optical images at the location of the lesion in a number of studies (66, 67) but no overall si gnificant difference has been found on meta-analysis (13). A reduction in oxygen can be seen in the region of the tumour in Figure 2 , and the tumour SatO 2 was calculated (54 6 2)% compared to (69 6 3)% in the background tissue but the quantative contrast between the tumour and the background SatO 2 is very small. The contrast is negative in all but one of the four patients on the initial scan, followed by an increase in SatO 2 to that of tissue background over the course of treatment. There was no obvious difference in the contrast of SatO 2 when comparing Grade II and Grade III lesions. Background SatO 2 was consistent between scans and between patients, over a range of 69-73%. This is comparable to published data (13).
The contrast between the lesion and the background at the start of treatment was greater in patients A and D who had a full or very good response to treatment (20.2 and 20.19 respectively), while Patients B and D, who were classified as having a partial response to treatment, had either positive contrast, or negligible contrast (0.17 and 20.009 respectively). These differences are very small, but are interesting and will be investigated with a larger patient cohort.
The optical images of breast cancer revealed an increase in absorption in the region of the tumour in all cases, presumably as a result of tumour angiogenesis and the increase in [HbT] . The contrast in absorption at 780 nm (due to absorption by Hb]) between the tumour ROI and the background in the range 2.6-5.9 were seen on initial baseline scans. Similar contrast has been seen by other groups (13). Over the course of treatment, the contrast for absorption at 780 nm decreased in all four patients. Changes (usually local decreases) in scatter are often also observed, although these may be due to parameter crosstalk (i.e. a localised change in absorption causing a small apparent change in scatter). Crosstalk was observed with previous phantom studies, described by Yates et al. (53) and in patient scans (52).
As already mentioned, other groups have investigated the use of optical tomography of the breast in monitoring treatment response. Scans performed by teams at both UCI and Dartmouth College have shown that scans performed early in treatment can reveal physiological changes in the tumour and could be used to predict final clinical outcome (44, 56) . The earliest into treatment that we were able to perform a scan was four weeks after the baseline scan prior to the start of treatment. An increase in the region of the tumour [HbT] was seen. The other three patients had scans at 5, 8 and 10 weeks after the start of treatment. A decrease in [HbT] in the region of the tumour was seen in these cases.
Meanwhile, we plan to continue scanning patients undergoing therapy with our imaging system, with the aim of using early physiological and optical changes to predict patient outcome. Further proposed work also includes investigating any correlation between the optical contrast of the tumour with respect to surrounding healthy tissue and MRI enhancement and contrast. Patients undergoing an experimental treatment of two weeks of endocrine therapy prior to surgery have been imaged prior to and after treatment, and the results from this cohort will hopefully be useful in examining early response to treatment. Whereas classical chemotherapy agents act as DNA disrupting drugs, endocrine therapy targets specific receptors on the surface cancer cells. A metabolic flare, due to changes in tumour metabolism, has been seen on PET scans in patients being treated with tamoxifen (68). We anticipate that on-going studies may be able to observe any differences in the changes of the local tumour physiology associated with the two forms of therapy.
Conclusion
We present the first long-term repeated studies of 3D optical imaging of the breast using a time-resolved, photon-counting system. Four women undergoing neoadjuvant chemotherapy for localised breast cancer were scanned to obtained 3D optical images of the uncompressed breast. One patient exhibited a complete response to treatment using both MRI and DOI. Another patient showed a complete response on DOI, and no remaining enhancement and residual scarring on MRI. Another patient exhibited a fall in tumour [HbT] and a 22 mm lesion with Type 2 enhancement on MRI at the end of treatment. All patients show a response in the SatO 2 in the tumour, with an increase or decrease in the tissue saturation towards that of background breast tissue. The data also shows reproducible, quantative values of [HbT] and SatO 2 in healthy background tissue over the course of treatment. These studies confirm that optical imaging of the breast offers a potentially powerful tool for monitoring long-term changes in the breast in response to primary medical therapy. Since optical scanning is safe, repeated scans over a long period can be performed without the exposure risks associated with x-ray imaging. The lack of compression also means that patients who may have sore breasts due to treatment effects can be imaged without discomfort. It will also allow co-registration with MRI images.
